BioSpace News Archive

Innovent Biologics, Inc. announces that the New Drug Application for parsaclisib for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two previous systemic therapies has been accepted for review by China’s Center for Drug Evaluation of the National Medical Products Administration and granted Priority Review designation.

Xeris Biopharma Holdings, Inc. announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 pm Pacific Time.

Aytu BioPharma, Inc., a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced a 1-for-20 reverse stock split of its outstanding common stock, effective at 12:01 a.m. Eastern time on January 6, 2023.

Relievant Medsystems announced that basivertebral nerve ablation received a Grade A Quality of Evidence Ranking with High Level of Certainty Regarding Net Benefit in the American Society of Pain & Neuroscience Evidence-Based Clinical Guideline of Interventional Treatments for Low Back Pain.

Hepion Pharmaceuticals, Inc. announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the NASH-TAG 2023 Conference, which is being held January 5-7, 2022, in Park City, Utah.

BD, a leading global medical technology company, announced that it will report financial results for its first quarter of fiscal year 2023 on Thursday, February 2, 2023.

QIAGEN announced an exclusive strategic partnership with California-based population genomics leader Helix to advance companion diagnostics for hereditary diseases.

Ophirex, Inc., a public benefit biotechnology company, announced the successful completion of a $37 million Series B financing, led by AXA IM Prime Impact Master Fund I SCA SICAV-RAIF.

Acorda Therapeutics, Inc. announced that on December 31, 2022 it entered into a new long-term global supply agreement with Catalent for the manufacture of INBRIJA at its Center of Excellence for Spray Dried Dispersions in Boston where Catalent will continue to manufacture INBRIJA through 2030.

Palvella Therapeutics, Inc., a late clinical-stage biopharmaceutical company whose vision is to become the leading rare disease company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases in indications for which there are no FDA-approved therapies, announced the initial closing of its Series D financing of up to $37.7 million.